Name of the Issue: Entero Healthcare Solutions Limited

1 Type of Issue (IPO / FPO)	IPO
-----------------------------	-----

2	Issue Size (Rs. in million)	16,000.00
	Fresh Issue (Rs. In million)	10,000.00
	Offer for Sale (Rs. In million)	6,000.00

*Source: Prospectus dated February 13, 2024

3 Grade of issue along with name of the rating agency

Name	Not Applicable
Grade	Not Applicable

4 Subscription Level (Number of times)* 1.32

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) On Allotment **	24.95
(ii) at the end of the 1st Quarter immediately after the listing (March 31, 2024)*	Not Available
(iii)at the end of 1st FY (March 31, 2024)*	Not Available
(iv) at the end of 2rd FY (March 31, 2025)*	Not Available
(v) at the end of 3rd FY (March 31, 2026)*	Not Available

^{**}Basis of Allotment

6 Financials of the issuer

(Consolidated Rs. in millions)

			(Oorioonaatoa rto: iii iiiiiiorio)
Parameters	1st FY (March 31, 2024)*	2nd FY (March 31, 2025)*	3rd FY (March 31, 2026)*
Net Sales/ Income from operations	Not Available	Not Available	Not Available
Net Profit for the year	Not Available	Not Available	Not Available
Paid-up equity share capital	Not Available	Not Available	Not Available
Reserves excluding revaluation reserves	Not Available	Not Available	Not Available

^{*}Financials not available as reporting for the relevant years has not been completed

7 Trading Status in the scrip of the issuer

Equity shares are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available

^{*} Information shall be updated in due course

8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)	None	None
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available	Not Available

^{*} Information shall be updated in due course

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	
(ii) Actual implementation	Not Available
(iii) Reasons for delay in implementation, if any	

Source: Source: Basis of allotment ad dated February 15, 2024

^{*}The above figure is before technical rejections.

^{*}QIB Holding not disclosed as reporting for relevant period has not been completed

10 Status of utilization of issue proceeds*

(i) as disclosed in the offer document

Particulars	Total estimated amount/ expenditure	Amount to be funded from the Net Proceeds	Estimated deployment of Net Proceeds in Financial Year 2024		Estimated deployment of Net Proceeds in Financial Year 2026
Repayment/prepayment, in full or part, of certain borrowings availed of by Company	1,425.00	1,425.00	1,425.00	-	-
Funding of long-term working capital requirements of the Company and its Subsidiaries during Fiscals 2025 and 2026	4,800.00	4,800.00	1,500.00	2,500.00	800.00
Pursuing inorganic growth initiatives through acquisitions*	2,370.00	2,370.00	600.00	1,770.00	-
General Corporate purposes*	917.00	917.00	93.00	480.00	344.00
Total Net Proceeds	9,512.00	9,512.00	3,618.00	4,750.00	1,144.00

^{*}Source: Prospectus

(ii) Actual utilization Rs. in Million

Particulars	Amount utilised from Net	Pending utilisation	
Tartouris	Proceeds	Fending utilisation	
Repayment/prepayment, in full or part, of certain borrowings availed of by Company	Not Available	Not Available	
Funding of long-term working capital requirements of the Company and its Subsidiaries during Fiscals 2025 and 2026	Not Available	Not Available	
Pursuing inorganic growth initiatives through acquisitions*	Not Available	Not Available	
General Corporate purposes*	Not Available	Not Available	
Total	Not Available	Not Available	

(iii) Reasons for deviations (if any)

11 Comments of monitoring agency, if applicable

a) Comments on use of funds	Not Available	ı
(b)Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	Not Available	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	Not Available	ĺ

12 Pricing Data

Designated Stock Exchange	BSE
Issue Price (Rs.)	1,258
Listing Date	February 16, 2024

Price parameters	At close of listing day March 12, 2024	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day (1)	As at the end of the 1st FY after the listing of the issue March 31, 2024				
				Closing price	High	Low		
Market Price on Designated Stock Exchange	1,149.50	1,010.85	Not Available	984.9	1258.00	974.45		
S & P BSE SENSEX	72,426.64	72,643.43	Not Available	73,651.35	74245.17	71674.42		
Sectoral Index	Not comparable to any of the available sectoral indices							

As at the end of the 3rd FY after the listing of the issue (As at the end of the 2nd FY after the listing of the issue (31st March, 2025)(1) 31st March, 2026)(1) Price parameters High High Low Low Closing price Closing price (during the FY) (during the FY) (during the FY) (during the FY) Market Price Not Available Not Available Not Available Not Available Not Available Not Available S & P BSE SENSEX Not Available Not Available Not Available Not Available Not Available Not Available

^{*}The amount to be utilised for general corporate purposes and inorganic growth initiatives does not individually exceed 25% of the Gross Proceeds respectively and does not exceed 35% collectively of the Gross Proceeds from the Fresh Issue, in accordance with Regulation 7(3) of the SEBI ICDR Regulations.

Sectoral Index

Not comparable to any of the available sectoral indices

Note: Stock Exchange data. Where the 30th day / 90th day/ March 31 of a particular year falls on a holiday, the immediately preceding trading day has been considered

(1) Price information not disclosed as reporting for the fiscal year has not been completed

13 Basis for Issue Price and Comparison with Peer Group & Industry Average

			As disclosed in the	At the end of 1st FY March	At the end of 1st FY	At the end of 1st
Accounting ratio		Face Value (Rs)	offer document	31, 2024**	March 31, 2025**	FY March 31,
						2026**
EPS	Issuer:	10	-3.43	Not available	Not available	Not available
	Peer group					
	MedPlus Health Services	2	4.17 / 4.17	Not available	Not available	Not available
	Limited (basic/diluted)					
P/E	Issuer:	10	NA	Not available	Not available	Not available
	Peer group					
	MedPlus Health Services	2	177.21	Not available	Not available	Not available
	Limited	Z				
RNoW	Issuer: Consolidated	10	-1.86%	Not available	Not available	Not available
	Peer group					
	MedPlus Health Services	2	3.36%	Not available	Not available	Not available
	Limited					
NAV	Issuer: Consolidated	10	174.21	Not available	Not available	Not available
	Peer group					
	MedPlus Health Services	2	124.93	Not available	Not available	Not available
	Limited					
(A) O						

⁽¹⁾ Sourced from Prospectus

14 Any other material information

For updates and material information please visit stock exchanges website www.bseindia.com and www.nseindia.com

All the above information is updated till April 1, 2024 unless indicated otherwise

Disclaimer

This document is uploaded by SBI Capital Markets Limited ("SBICAP") on its website pursuant to the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012, without having regard to specific objectives, suitability, financial situations and needs of any particular person and does not constitute any recommendation, and should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities mentioned therein, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. Nothing in these materials is intended by SBICAP to be construed as legal, accounting or tax advice. Past performance is not a guide for future performance. Neither SBICAP and its affiliates, nor its' directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of this document.

The information contained in this document is based on the Red Herring Prospectus and amendments thereto, if any, and/or the Final Prospectus, as amended, if any, as applicable, of the Issuer ("Offer Documents") and the information as provided by the Issuer to SBICAP and available with or provided by the Stock Exchanges / Regulators / Monitoring Agencies from time to time. SBICAP reserves the right to make amendments to this document as and when it deems necessary and also to make additions or deletions to the information contained herein from time to time.

In this context, the 'Issuer" would mean an issuer who has come out with the public issue of its securities as indicated in this document for the respective issues, whose information is being accessed by any person, in this document. The Directors of the Issuer have confirmed in the relevant Offer Documents that the information made available therein is true, fair, correct and adequate. SBICAP has made efforts to ensure that the information is gathered from authentic sources, however, no representation or warranty, expressed or implied, is made or given by or on behalf of SBICAP or its affiliates, nor any person who controls it or any director, officer, employee, advisor or agent of it, or affiliate of any such persons as to the accuracy, authenticity, correctness, completeness or fairness of the information contained in this document and SBICAP or its affiliates or such persons do not accept any responsibility or liability for any such information and therefore, any liability or responsibility is expressly disclaimed. This document has not been approved and will or may not be reviewed or approved by any statutory or regulatory authority in India or by any Stock Exchange in India. This document may not be all inclusive and may not contain all of the information that the recipient may consider material.

Since neither this document nor any copy of it may be taken or transmitted or distributed or re-distributed into certain jurisdictions, directly or indirectly, which may be restricted by law, persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither SBICAP, nor any of its affiliates nor their respective directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you may incur in the event of any failure or disruption of this website, or resulting from the act or omission of any party involved in producing or hosting this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access or use of the website or these materials.

This document is issued by SBI Capital Markets Limited without any liability / undertaking / commitment on the part of itself or State Bank of India or any other entity in the State Bank Group, except where it is explicitly stated. Further, in case of any commitment on behalf of State Bank of India or any other entity in the State Bank Group, except where it is explicitly stated. Further, in

^{*}Not available as the relevant fiscal year has not been completed / information not disclosed

